Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option for patients. The subcutaneous form of Keytruda showed to deliver the same ...

While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

The FDA approved the use of pembrolizumab (Keytruda; Merck) and berahyaluronidase alfa-pmph (Keytruda Qlex; Merck) for use in patients 12 years and older with solid tumor indications approved for the ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients. The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...

The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately to severely ...